Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Erythematous rash following romiplostim administration in a patient with autoimmune lymphoproliferative syndrome.

Biondo L, Bodge M, Paul SR.

Ann Pharmacother. 2013 Jan;47(1):e7. doi: 10.1345/aph.1R361. Epub 2013 Jan 8.

PMID:
23300150
2.

Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.

Newland A, Godeau B, Priego V, Viallard JF, López Fernández MF, Orejudos A, Eisen M.

Br J Haematol. 2016 Jan;172(2):262-73. doi: 10.1111/bjh.13827. Epub 2015 Nov 5.

PMID:
26537623
3.

Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.

Al-Jafar H, Giagounidis A, El-Rashaid K, Al-Ali M, Hakim AA.

Ann Pharmacother. 2012 Nov;46(11):e31. doi: 10.1345/aph.1R134. Epub 2012 Oct 31.

PMID:
23115229
4.

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy.

Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP.

Blood. 2010 Oct 28;116(17):3163-70. doi: 10.1182/blood-2010-03-274753. Epub 2010 Jul 14.

5.

Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist.

LaMoreaux B, Barbar-Smiley F, Ardoin S, Madhoun H.

Semin Arthritis Rheum. 2016 Feb;45(4):e10-2. doi: 10.1016/j.semarthrit.2015.07.008. Epub 2015 Jul 29.

PMID:
26329147
7.

The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.

Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M.

J Clin Pharm Ther. 2014 Aug;39(4):376-82. doi: 10.1111/jcpt.12156. Epub 2014 Apr 4.

PMID:
24702274
8.

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy.

Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, Viallard JF, Macik G, Rummel M, Nie K, Jun S.

Br J Haematol. 2013 May;161(3):411-23. doi: 10.1111/bjh.12260. Epub 2013 Feb 22.

PMID:
23432528
9.

Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP).

Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL.

J Thromb Haemost. 2010 Jun;8(6):1372-82. doi: 10.1111/j.1538-7836.2010.03830.x. Epub 2010 Mar 3.

10.

Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.

Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N.

Appl Health Econ Health Policy. 2013 Oct;11(5):457-69. doi: 10.1007/s40258-013-0044-y. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):687.

11.

Deep vein thrombosis associated with a single dose of romiplostim in a high-risk patient.

Przespo E, Elefante A.

Am J Health Syst Pharm. 2012 Jan 15;69(2):131-3. doi: 10.2146/ajhp100673.

PMID:
22215358
12.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
13.

Romiplostim or standard of care in patients with immune thrombocytopenia.

Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, Rodeghiero F, Chong BH, Wang X, Berger DP.

N Engl J Med. 2010 Nov 11;363(20):1889-99. doi: 10.1056/NEJMoa1002625.

14.

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

J Clin Oncol. 2010 Jan 20;28(3):437-44. doi: 10.1200/JCO.2009.24.7999. Epub 2009 Dec 14.

PMID:
20008626
15.

Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.

J Clin Pharm Ther. 2012 Dec;37(6):729-32. doi: 10.1111/j.1365-2710.2012.01353.x. Epub 2012 May 14.

PMID:
22583038
16.

Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports.

Voican CS, Naveau S, Perlemuter G.

Eur J Gastroenterol Hepatol. 2012 Dec;24(12):1455-8. doi: 10.1097/MEG.0b013e328357d5f2.

PMID:
22890208
17.

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.

Kohn B, Bal G, Chirek A, Rehbein S, Salama A.

BMC Vet Res. 2016 Jun 10;12:96. doi: 10.1186/s12917-016-0718-4. Erratum in: BMC Vet Res. 2016 Dec 30;12 (1):290.

18.

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma.

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Pathol Oncol Res. 2011 Mar;17(1):141-3. doi: 10.1007/s12253-010-9276-4. Epub 2010 Jul 14.

PMID:
20628840
19.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.

Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.

Blood. 2011 Oct 20;118(16):4338-45. doi: 10.1182/blood-2011-03-340166. Epub 2011 Aug 10.

20.

Increased requirement for platelet transfusions concurrent with enhanced bleeding during romiplostim treatment in a patient with thrombocytopenia due to bone marrow failure.

Lotfi R, Moeller P, Schmid M, Schrezenmeier H.

Ann Hematol. 2011 Nov;90(11):1357-9. doi: 10.1007/s00277-011-1180-9. Epub 2011 Feb 16. No abstract available.

PMID:
21327404

Supplemental Content

Support Center